Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd., together with its subsidiaries, operates as a pharmaceutical manufacturing holding investment company in China. The company engages in the research and development, and production of anti-tumor, cardiovascular, cerebrovascular, rheumatism bone pain, tonic and sedative, cold and cough, anti-fungal, gynecology, and other treatment fiel… Read more
Market Cap & Net Worth: Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A (600613)
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A (SHG:600613) has a market capitalization of $414.17 Million (CN¥3.04 Billion) as of March 18, 2026. Listed on the SHG stock exchange, this China-based company holds position #13738 globally and #3572 in its home market, demonstrating a 2.26% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A's stock price CN¥6.34 by its total outstanding shares 479319978 (479.32 Million).
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A Market Cap History: 2015 to 2026
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A's market capitalization history from 2015 to 2026. Data shows change from $1.35 Billion to $414.17 Million (-11.11% CAGR).
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.22x
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A's market cap is 0.22 times its annual revenue
0.84x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
6.28x
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A's market cap is 6.28 times its annual earnings
11.15x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.35 Billion | $1.59 Billion | $216.73 Million | 0.85x | 6.22x |
| 2016 | $880.44 Million | $1.60 Billion | $182.06 Million | 0.55x | 4.84x |
| 2017 | $526.22 Million | $1.74 Billion | $129.60 Million | 0.30x | 4.06x |
| 2018 | $310.52 Million | $1.85 Billion | $106.09 Million | 0.17x | 2.93x |
| 2019 | $456.61 Million | $1.93 Billion | $83.97 Million | 0.24x | 5.44x |
| 2020 | $309.89 Million | $1.82 Billion | -$353.47 Million | 0.17x | N/A |
| 2021 | $406.01 Million | $2.30 Billion | $69.62 Million | 0.18x | 5.83x |
| 2022 | $529.32 Million | $2.39 Billion | $48.55 Million | 0.22x | 10.90x |
| 2023 | $497.14 Million | $2.34 Billion | $57.00 Million | 0.21x | 8.72x |
| 2024 | $448.14 Million | $2.05 Billion | $71.39 Million | 0.22x | 6.28x |
Competitor Companies of 600613 by Market Capitalization
Companies near Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A in the global market cap rankings as of March 18, 2026.
Key companies related to Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $883.37 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #18 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #29 globally with a market cap of $390.88 Billion USD.
- AstraZeneca PLC (NASDAQ:AZN): Ranked #46 globally with a market cap of $296.35 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #15 | Eli Lilly and Company | NYSE:LLY | $883.37 Billion | $989.12 |
| #18 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $243.19 |
| #29 | AbbVie Inc | NYSE:ABBV | $390.88 Billion | $221.45 |
| #46 | AstraZeneca PLC | NASDAQ:AZN | $296.35 Billion | $192.01 |
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A Historical Marketcap From 2015 to 2026
Between 2015 and today, Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A's market cap moved from $1.35 Billion to $ 414.17 Million, with a yearly change of -11.11%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥414.17 Million | +4.45% |
| 2025 | CN¥396.53 Million | -11.52% |
| 2024 | CN¥448.14 Million | -9.86% |
| 2023 | CN¥497.14 Million | -6.08% |
| 2022 | CN¥529.32 Million | +30.37% |
| 2021 | CN¥406.01 Million | +31.02% |
| 2020 | CN¥309.89 Million | -32.13% |
| 2019 | CN¥456.61 Million | +47.05% |
| 2018 | CN¥310.52 Million | -40.99% |
| 2017 | CN¥526.22 Million | -40.23% |
| 2016 | CN¥880.44 Million | -34.65% |
| 2015 | CN¥1.35 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $414.17 Million USD |
| MoneyControl | $414.17 Million USD |
| MarketWatch | $414.17 Million USD |
| marketcap.company | $414.17 Million USD |
| Reuters | $414.17 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.